Replies: 1 comment 1 reply
-
|
It is our aim to eventually allow individuals to do mutation RBFEs with arbitrarily modified residues. However the path to enabling this requires the completion of a few ongoing/hopefully upcoming tasks;
We hope that some of these tasks may be prioritised in our next roadmap. That being said, thinking about the science only, it is my understanding from discussions with our TAC that whether or not one should mutate post or pre covalent binding is still unresolved. |
Beta Was this translation helpful? Give feedback.
1 reply
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment
Uh oh!
There was an error while loading. Please reload this page.
-
This is for comparing covalent inhibitors - some papers seem to suggest that you can just use rbfe between the covalent states of the ligands instead of modeling the whole cycle of bond forming/breaking (e.g. https://doi.org/10.1021/acs.jcim.1c00515). I wonder if the implementation of this would overlap with the work done for protein mutations #1500 i.e. could the bound ligands be considered special residues. Any thoughts @ijpulidos
Beta Was this translation helpful? Give feedback.
All reactions